Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate

Human Psychopharmacology

Volumn 23, Issue 1, 2008, Pages 13-20

  Roth, Thomas ^a   Mayleben, David ^b   Corser, Bruce C ^c   Singh, Nikhilesh N ^d  

^a HENRY FORD HOSPITAL   (United States)

^b Community Research ^*  (United States)

^c Sleep Management Institute   (United States)

^d Transcept Pharmaceuticals Inc   (United States)

Author keywords

MOTN insomnia; Pharmacodynamics; Pharmacokinetics; Zolpidem

Indexed keywords

IBUPROFEN; INTERMEZZO; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; ZOLPIDEM TARTRATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSMENORRHEA; EPIGASTRIC PAIN; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LOW DRUG DOSE; LOZENGE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SINGLE DRUG DOSE; SLEEP PATTERN; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALYSIS OF VARIANCE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PAIN MEASUREMENT; PSYCHOMOTOR PERFORMANCE; PYRIDINES; TIME FACTORS;

EID: 38649092005     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.884     Document Type: Article

References (17)

1. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. 1998. Comparative kinetics, and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 64: 553-561.
2. Hohagen F, Kappler C, Schramm E, et al. 1994a. Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand 902: 102-108.
3. Hohagen F, Kappler C, Schramm E, et al. 1994b. Sleep onset insomnia; sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 17: 551-554.
4. Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. 1997. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37: 693-703.
5. Mellinger G, Balter M, Uhlenhuth E. 1985. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatr 42: 225-232.
6. Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. 2003. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med 4(6): 553-561.
7. Patat A, Trocheries S, Thebault JJ, et al. 1994. EEG profile of intra venous zolpidem in healthy volunteers. Psychopharmacol (Berlin) 114: 138-146.
8. Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, Allard S. 1996. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 34(4): 178-183.
9. Roehrs T, Merlotti L, Zorick F, Roth T. 1994. Sedative, memory, and performance effects of hypnotics. Psychopharmacol 116: 130-134.
10. Rosenberg RP. 2006. Sleep maintenance insomnia: strengths and weaknesses of current therapies. Ann Clin Psychiatry 18(1): 49-56.
11. Roth T, Corser B, Singh N, et al. 2006. Daytime pharmacokinetic and pharmacodynamic evaluation of low-dose transmucosal zolpidem. Sleep 29 (Abstract Supplement): A46.
12. Scharf MB, Roth T, Vogel GW, Walsh JK. 1994. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatr 55(9): 192-199.
13. Shader RI, Dreyfuss D, Gerrein JR, et al. 1986. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Therap 39: 526-529.
14. Shochat T, Umphress J, Israel A, Ancoli-Israel S. 1999. Insomnia in primary care patients. Sleep 22(Suppl. 2): 359-365.
15. Soubrane C, Walsh J, Roth T. 2005. Zolpidem modified-release improves sleep induction, sleep maintenance, sleep duration, and quality of sleep without next-day residual effects in adults with primary insomnia. Sleep 28: A244.
16. Stone BM. 1984. Pencil and paper tests: sensitivity to psychotropic drugs. Brit J Clin Pharmacol 18 (Suppl. 1): 15S-20S.
17. Verster JC, Volkerts ER, Schreuder AH, et al. 2002. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 22(6): 576-583.